Research Article
Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study
Table 1
Baseline characteristics of patients on metformin and nonmetformin monotherapy before and after propensity score matching.
| | Before propensity score matching | After propensity score matching | | Total () | Metformin monotherapy () | Nonmetformin monotherapy () | value | Total () | Metformin monotherapy () | Nonmetformin monotherapy () | value |
| | Demographics | | | | | | | | | | Age, in years () | | | | <0.001 | | | | <0.001 | | Age (% of <65 years) | 14,739 (61.2) | 3708 (67.5) | 11,031 (59.3) | <0.001 | 7391 (67.4) | 3699 (67.5) | 3692 (67.4) | 0.887 | | Sex (% of males) | 10,475 (43.5) | 2497 (45.5) | 7978 (42.9) | <0.001 | 5008 (45.7) | 2491 (45.4) | 2517 (45.9) | 0.618 | | Hospital level (% of secondary) | 5417 (22.5) | 1933 (35.2) | 3484 (18.7) | <0.001 | 3846 (35.1) | 1924 (35.1) | 1922 (35.1) | 0.968 | | Laboratory measurements | | | | | | | | | | HbA1c level (%) () | | | | 0.115 | | | | 0.862 | | HbA1c level group (% of <7%) | 1189 (67.2) | 385 (65.8) | 804 (67.9) | 0.391 | 734 (64.9) | 377 (65.5) | 360 (64.3) | 0.681 | | Comorbidity | | | | | | | | | | Hypertension (%) | 14,076 (58.4) | 3677 (67.0) | 10,399 (55.9) | <0.001 | 7361 (67.1) | 3668 (66.9) | 3693 (67.4) | 0.611 | | Hyperlipidemia (%) | 2483 (10.3) | 727 (13.2) | 1756 (9.4) | <0.001 | 1422 (13.0) | 720 (13.1) | 702 (12.8) | 0.609 | | Coronary heart disease (%) | 11,195 (46.5) | 2701 (49.2) | 8494 (45.7) | <0.001 | 5523 (50.4) | 2694 (49.2) | 2826 (51.6) | 0.014 | | Stroke (%) | 7574 (31.4) | 1763 (32.1) | 5811 (31.2) | 0.218 | 3502 (31.9) | 1761 (32.1) | 1741 (31.8) | 0.682 | | Cancer (%) | 398 (1.7) | 103 (1.9) | 288 (1.6) | <0.001 | 175 (1.6) | 94 (1.7) | 86 (1.6) | 0.063 |
|
|
Abbreviations: HbA1c: glycated hemoglobin A1c; SD: standard deviation.
|
